AZTA (Life Sciences Tools & Services) Stock Valuation & Fair Value Significantly overvalued
AZTA (Life Sciences Tools & Services) trades at a blended P/E of 71.6, about 77% above its historical normal valuation, with a forward growth estimate of 40.4% and a PEG of 1.77. Analysts' one-year estimates have been hit 18% of the time.
Valuation flags
- Overvalued by 77%
Frequently asked questions
Is AZTA overvalued?
At a blended P/E of 71.6 versus its historical normal P/E of 40.5, AZTA trades about 77% above its typical valuation, with a PEG of 1.77 on 40.4% forward growth. tickerseer currently rates it significantly overvalued.
What is AZTA's fair value and PEG?
AZTA trades at a blended P/E of 71.6 against a historical normal P/E of 40.5, a PEG of 1.77, and a forward growth estimate of 40.4%.
Has tickerseer's rating of AZTA changed?
tickerseer's rating has been significantly overvalued since 2026-07-31.
Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.